WireSift
← AI Adoption Tracker
WireSift Research · AI Adoption Tracker · Q1 2026

ALGNAlign Technology, Inc.

AI adoption · Q1 2026 earnings call

Health CareExploring
AI mentions
1
extracted from this call
Max specificity
2 / 5
directional only
AI revenue
Not disclosed
no breakout in this call
AI was mentioned only once on this call, briefly and in passing by CEO Joe Hogan in his closing prepared remarks, framing AI-enabled treatment planning as a long-term investment that improves predictability, efficiency, and scalability. No analyst asked about AI, no financial metrics were attributed to AI, and no specific AI products, partnerships, or investments were discussed. The mention was high-level and aspirational, with no quantification.
Public Company AI Adoption Index
Adopter
See full leaderboard →
Composite
17/ 100
#248 non-tech · #315 overall · #39 in Health Care
Depth · 40%
24
stage: exploring · max spec: 2
Disclosure · 40%
0
no quantified disclosure
Breadth · 20%
35
1 scope
Adoption scopes:product_embedded
Every claim, sourced

1 AI mention from this call.

Extracted verbatim from the ALGN Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.

  • T2Prepared remarks· CEO· Product-embedded AI
    we continue to benefit from long-term investments in AI-enabled treatment planning and integrated digital workflows that improve predictability, efficiency and scalability across the business. These capabilities are designed to increase planning consistency and throughput and support more predictable outcomes for doctors helping us operate more efficiently across volume environments.
    Joseph Hogan, ALGN earnings call
Q&A Dynamics

What management wouldn’t quantify.

Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.

  1. No quantification of AI investment (capex or opex) was provided.
  2. No revenue attribution to AI-enabled products or features was disclosed.
  3. No adoption metrics, productivity metrics, or outcome data tied to AI treatment planning were shared.
  4. No analyst asked about AI specifically; management volunteered only a single brief mention.
  5. The specific AI technologies, models, or platforms underlying 'AI-enabled treatment planning' were not named.
Stay informed

Independent research, direct to your inbox.

Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.

By subscribing, you agree to our Privacy Policy.

Sourced from primary documents · See the methodology for the extraction approach.